Potential of microRNAs for cancer diagnostics, prognostication and therapy

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 655-659

  Garzon, Ramiro ^a   Marcucci, Guido ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

diagnosis; microRNA; prognosis; therapeutics

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BORTEZOMIB; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; MICRORNA; MICRORNA 122; MICRORNA 155; MICRORNA 181; MICRORNA 21; MICRORNA 29A; MICRORNA 29B; MICRORNA 92A; MIRAVIRSEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER THERAPY; CELL PROLIFERATION; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS; TRANSCRIPTOME;

EID: 84868256341     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328358522c     Document Type: Review

References (38)

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-854.
2. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Gen 2011; 12:99-110.
3. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Drug Rev 2010; 10:775-789.
4. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-838.
5. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008; 26:462-469.
6. Rosenwald S, Gilad S, Benjamin S, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 2010; 23:814-823.
7. Varadhachary GR, Spector Y, Abbruzzese JL, et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 2011; 17:4063-4070.
8. Ferracin M, Pedriali M, Veronese A, et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol 2011; 25:43-53.
9. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as noninvasive biomarkers for cancer. Mol Cancer 2010; 9:306.
10. Cortez A, Bueso-Ramos C, Ferdin F, et al. MicroRNAs in body fluids: the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011; 8:467-477.
11. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105:10513-10518.
12. Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012; 106:768-774.
13. Huang Z, Huang D, Shujuan N, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2009; 127:118-126.
14. Cheng H, Zhang L, Cogdell D, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011; 6:e17745.
15. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011; 108:3713-3718.
16. Foss KM, Sima C, Ugolini D, et al. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage nonsmall cell lung cancer. J Thorac Oncol 2011; 6:482-488.
17. Hennessey P, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 2012; 7:e32307.
18. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50:298-301.
19. Yanaihara N, Caplen N, Bowman E, et al. MicroRNA expression signature predicts lung cancer diagnosis and prognosis. Cancer Cell 2006; 9:189-198.
20. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1919-1928.
21. Schwind S, Maharry K, Radmacher MD, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28:5257-5264.
22. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107:7473-7478.
23. Garzon R, Liu S, Fabbri M, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009; 113:6411-6418.
24. Hwang J-H, Voortman J, Giovannetti E, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5:e10630.
25. Garzon R, Heaphy CE, Havelange V, et al. MicroRNA-29b functions in AML. Blood 2010; 114:5331-5341.
26. Liu S, Wu LC, Pang JL, et al. Evidence of microRNA-29b and Sp1/NFkBHDAC regulatory network for KIT expression in KIT-driven acute myeloid leukemia (AML): biologic and therapeutic implications. Cancer Cell 2010; 17:333-347.
27. Gumireddy K, Young DD, Xiong X, et al. Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl 2008; 47:7482-7484.
28. Connelly CM, Thomas M, Deiters A. High-throughput luciferase reporter assay for small-molecule inhibitors of microRNA function. J Biomol Screen 2012; 17:822-828.
29. Young DD, Connelly CM, Grohmann C, Deiters A. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. Am Chem Soc 2010; 132:7976-7981.
30. Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 2012; 119:6025-6031.
31. Weiler J, Hunziker J, Hall J, et al. AntimiRNA oligonucleotides (AMOs); amunition to target miRNAs implicated in human disease? Gene Ther 2006; 13:496-502.
32. Krutzfeldt J, Rajewski N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438:685-689.
33. Vester B, Wengel J. LNA (locked nucleic acid): high affinity targeting of complementary RNA and DNA. Biochemistry 2004; 43:13233-13241.
34. Elmén J, Lindow M, Schütz S, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008; 36:1153-1162.
35. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis c virus infection. Science 2010; 327:198-201.
36. Stenvang S, Petri A, Lindow M, et al. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012; 3:1.
37. Janssen HL, Reesink HW, Zeuzem S. A randomized, double-blind, placebo (plb) controlled safety and antiviral proof of concept study of miravirsen (MIR), an oligonucleotide targeting miR-122, in treatment na?̈ve patients with genotype 1 (gt1) chronic HCV infection [abstract]. Hepatology 2011; 54:1430A.
38. Kota J, Hivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137:1005-1017.